Celgene Corporation Announces Appointment of Dr. Alise Reicin to President, Global Clinical Development
October 22 2018 - 4:30PM
Business Wire
Dr. Alise Reicin will lead mid- to late-stage
drug development across Celgene’s portfolio
New organizational structure enhances corporate
strategy and focus on discovery, development and
commercialization
Celgene Corporation (NASDAQ:CELG) today announced the
appointment of Dr. Alise Reicin to President, Global Clinical
Development, reporting to Mark J. Alles, Chairman and Chief
Executive Officer, effective November 1, 2018. In this role, Dr.
Reicin will be responsible for all aspects of mid- to late-stage
clinical development across Celgene’s portfolio and will serve on
the company's Executive Committee.
“Dr. Reicin is an accomplished physician with an excellent
record of developing important therapeutics for multiple cancer and
inflammatory indications,” said Mark J. Alles, Chairman and CEO of
Celgene Corporation. “Led by Alise, our clinical development
organization will be structured to more completely align with our
strategy and mission to discover, develop and commercialize
innovative therapies for patients with unmet need. She joins Dr.
Rupert Vessey, President, Research & Early Development, and Dr.
Jay Backstrom, Chief Medical Officer, as we deliver the potential
of our deep and broad pipeline.”
The appointment of Dr. Reicin is part of a deliberate strategy
to strengthen Celgene for long-term success. This organizational
change further establishes clinical development as another center
of excellence and enhances strategic leadership in discovery,
development and commercialization. Dr. Rupert Vessey continues to
lead early research and development. Dr. Reicin will lead mid- to
late-stage clinical development, clinical operations,
biostatistics, project leadership and project management. Dr. Jay
Backstrom maintains responsibility for our global regulatory
strategy, drug safety, regulatory operations and pharmacovigilance.
Nadim Ahmed and Terrie Curran continue to lead our global
commercial and medical affairs organizations for the Hematology
& Oncology and Inflammation & Immunology franchises,
respectively.
Dr. Reicin was most recently Senior Vice President and Head of
Global Clinical Development in Research and Development (R&D)
at EMD Serono, the biopharmaceutical business of Merck KGaA,
Darmstadt, Germany. In this role, she has been responsible for the
clinical development of assets across oncology and inflammatory
indications, including anti-PD-L1 avelumab in solid tumors and
cladribine in relapsing multiple sclerosis. Since joining EMD
Serono in 2015, she has led clinical development, biostatistics,
clinical operations, and the Japan and China R&D hubs. Prior to
joining EMD Serono, Dr. Reicin served as Vice President, Project
and Pipeline Leadership, Oncology Franchise at Merck, Sharp &
Dohme (Merck). She led Merck’s immuno-oncology program and oversaw
initial development and filing activities worldwide, including the
first approval for pembrolizumab (KEYTRUDA®) in the United States.
Before joining Merck, Dr. Reicin was a faculty member at Columbia
Medical School, and a physician and researcher at Columbia
Presbyterian Hospital. She has a degree in biochemistry from
Barnard College of Columbia University. She received her Medical
Degree from Harvard Medical School, where she was enrolled in the
Health Sciences and Technology program with MIT (Massachusetts
Institute of Technology).
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
Forward-Looking Statement
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181022005907/en/
CelgeneInvestors:908-673-9628ir@celgene.comorMedia:908-673-2275media@celgene.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024